Executive Vice President, Chief Operating and Financial Officer · Vertex Pharmaceuticals Inc (VRTX)

Charles Wagner

A named executive officer of Vertex Pharmaceuticals in every fiscal year CompBrief holds from FY2019 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$8,241,809

FY2024: $7,999,440

3rd of 6 named executive officers at Vertex Pharmaceuticals by FY2025 total.

6 named officers on file for Vertex Pharmaceuticals, FY2025

See an example →

What this number hides

The filing gives the total. Vertex Pharmaceuticals’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Vertex Pharmaceuticals’s whole pay program stands against its peers

  • Vertex Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 2, 2026 (DEF 14A).

Free

Get Charles Wagner’s full pay file as a PDF — free

More than this page: up to 10 years of Charles’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Charles Wagner and every company like it: Velarion Intel, free for 3 days, no card →

Charles Wagner compensation by year

Vertex Pharmaceuticals Summary Compensation Table · all 7 fiscal years held
In US dollars, as Vertex Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Salary$492,692$726,923$729,615$793,269$825,000$876,443$974,808
Bonus$140,000$0$0$0$0$0$0
Stock awards$1,225,383$4,375,585$4,375,430$3,750,197$5,250,552$5,250,328$5,250,817
Option awards$600,039$0$0$0$0$0$0
Non-equity incentive$992,250$946,680$1,078,539$1,239,315$1,256,063$1,821,150$1,965,000
Pension and deferred compensation$0$0$0$0$0$0$0
All other$36,849$41,202$40,348$28,830$40,136$51,519$51,184
Total$3,487,213$6,090,390$6,223,932$5,811,611$7,371,751$7,999,440$8,241,809

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 2, 2026, accession 0000875320-26-000153, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0000875320-26-000153. Every figure is read from that document and cited to the page and table it appears in. Filed April 2, 2026.

$3.5M
$6.1M
$6.2M
$5.8M
$7.4M
$8.0M
$8.2M
FY19
FY20
FY21
FY22
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU9,440$4,279,718—
PSU7,114$3,225,203—
PSU6,656$3,017,564—
RSU6,655$3,017,111—
RSU4,744$2,150,740—
RSU4,743$2,150,286—
RSU4,160$1,885,978—
PSU3,148$1,427,177—
RSU3,147$1,426,724—

Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Vertex Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Reshma KewalramaniChief Executive Officer and President$21,144,261
Stuart ArbuckleFormer Executive Vice President, Chief Operating Officer$9,996,347
Charles Wagner · this pageExecutive Vice President, Chief Operating and Financial Officer$8,241,809
Nia TatsisExecutive Vice President, Chief Regulatory and Quality Officer$6,974,920
Amit SachdevExecutive Vice President, Chief Patient and External Affairs Officer$6,777,243
Carmen BozicExecutive Vice President, Chief Medical Officer$6,646,321

Charles Wagner's compensation dossier, Vertex Pharmaceuticals

You have read Charles Wagner's totals and holdings. The dossier adds each equity grant Vertex Pharmaceuticals disclosed for Charles Wagner and Vertex Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Vertex Pharmaceuticals compensation record

free company brief

This page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vertex Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Vertex Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order VRTX

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Charles Wagner's compensation dossier